Search clinical trials for: Trastuzumab NK cells

Total 10620 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Metastatic Breast Cancer | Metastatic Gastric Cancer

China
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Breast Cancer

United States
The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Withdrawn

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Breast Cancer
Shanghai GeneChem Co., Ltd.
Shanghai Cancer Hospital, China

Unknown

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Carcinoma, Hepatocellular | Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

China
Maxivax SA

Active, not recruiting

MVX-ONCO-1 in Patients With Solid Tumor

Cancer | Solid Tumor

Switzerland
Amit, Patel N, M.D.

Terminated

Autologous/Allogeneic Progenitor Stem Cell Therapy for Congestive Heart Failure

Heart Failure, Congestive
Oslo University Hospital

Completed

Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

Glioblastoma | Brain Tumor
Medical University of Vienna
Daiichi Sankyo, Inc.

Completed

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases (TUXEDO-1)

Breast Cancer Stage IV

Austria
Meiji Seika Pharma Co., Ltd.
Dong-A Pharmaceutical

Completed

Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

Healthy Volunteer

Japan
Armando Santoro, MD

Terminated

Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients

NON-SMALL CELL LUNG CANCER

Italy
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Dana-Farber Cancer Institute

Recruiting

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Leukemia, Myeloid | Myeloproliferative Disorders | Myeloproliferative Neoplasm

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

HER2-positive Gastric Cancer
Anglo Celtic Cooperative Oncology Group

Completed

Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Breast Cancer

United Kingdom
Warwick Medical School

Unknown

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

Breast Cancer

United Kingdom
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
Comprehensive Support Project for Oncology Research

Completed

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT] (RESPECT)

Breast Cancer

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Shahid Beheshti University of Medical Sciences

Not yet recruiting

Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

Iran, Islamic Republic of
Xinqiao Hospital of Chongqing
Chongqing Precision Biotech Co., Ltd

Not yet recruiting

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

NHL

China
Gamida Cell ltd

Terminated

Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Non-Hodgkin Lymphoma

United States
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Esophagogastric Cancer

United States
Shanghai Zhongshan Hospital

Completed

Trastuzumab Based Therapy in HER2 Positive AGC

Gastric Adenocarcinoma

China
National Cancer Institute, France

Completed

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

Breast Cancer

France
AstraZeneca
Daiichi Sankyo Co., Ltd.

Completed

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Jules Bordet Institute
Roche Pharma AG

Active, not recruiting

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 (ZEPHIR)

HER-2 Positive Breast Cancer

Belgium, Netherlands
Byondis B.V.

Completed

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Solid Tumors

Netherlands, Belgium, United Kingdom, Spain
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Breast Cancer

United States
Enlivex Therapeutics Ltd.

Terminated

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

Covid19

Israel
Roswell Park Cancer Institute

Completed

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States
Finnish Breast Cancer Group

Completed

The Synergism Or Long Duration (SOLD) Study (SOLD)

Breast Neoplasms

Finland
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Al-Azhar University
Cairo University

Completed

MSCs For Treatment of Azoospermic Patients

Male Infertility

Egypt
Fuda Cancer Hospital, Guangzhou
Jinan University Guangzhou

Completed

Safety and Efficiency of γδ T Cell Against Lung Cancer

Lung Cancer

China
MedSIR
Daiichi Sankyo, Inc.

Not yet recruiting

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4)

Breast Cancer | Metastatic Breast Cancer
Anterogen Co., Ltd.

Terminated

Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211) (ANTG)

Perianal Fistula | Primary; Complex

Korea, Republic of
Anterogen Co., Ltd.

Terminated

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula (ANTG-ASC-210)

Complex Perianal Fistula

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Estonia, Hungary, Turkey, Israel, Slovakia, Bulgaria, Lithuania, Macedonia, The Former Yugoslav Republic of
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Breast Cancer

United States
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
University of Alabama at Birmingham

Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Breast Cancer

United States
Genor Biopharma Co., Ltd.

Completed

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Metastatic Breast Cancer

Australia
Jules Bordet Institute

Unknown

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

Breast Cancer | Metastatic Cancer

Belgium
National Cancer Centre, Singapore

Completed

A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

HER 2 Positive Advanced Gastric Cancer

Singapore
Cancer Trials Ireland

Recruiting

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

HER2-positive Breast Cancer

Ireland
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Breast Cancer
Wuhan Union Hospital, China
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's Lymphoma

China
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States

3

Subscribe